文献速递青光眼

开发一种Δ9-四氢大麻酚氨基酸-二羧酸酯前药,提高眼部生物利用度

Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

本研究合成并表征了Δ9-四氢大麻酚(THC)的缬氨酸单酯、二酯及缬氨酸-半琥珀酸酯前药,评估其水溶性、体外角膜通透性及在α-糜蛋白酶诱导兔青光眼模型中的降眼压活性。THC-Val-HS(缬氨酸-半琥珀酸酯)溶解度和体外通透性显著优于THC,局部给药后可将THC递送至眼前段组织,降眼压持续时间较THC延长1小时、幅度增大10%,与毛果芸香碱滴眼液相当。

要点

  • THC-Val-HS的溶解度较THC提高96倍,体外角膜通透性也明显改善。
  • THC-Val-HS降眼压持续时间较THC延长1小时,降幅较THC增大10%,与毛果芸香碱滴眼液相当。
  • 噻吗洛尔滴眼液的降眼压作用持续时间长于THC-Val-HS。

核心结论

  • 前药衍生化与制剂开发相结合的策略显著改善了THC局部滴眼后进入眼前段的渗透性.
  • 眼部渗透性增强使降眼压活性显著提高。

研究设计与样本

  • 研究合成并化学表征了THC-Val、THC-Val-Val和THC-Val-HS三种前药。
  • 测定了THC及前药在不同表面活性剂和环糊精存在下的水溶解度和体外角膜通透性。
  • 在α-糜蛋白酶诱导的兔青光眼模型中评估两种制剂的治疗活性,对照包括THC乳剂、市售马来酸噻吗洛尔和毛果芸香碱滴眼液。

主要发现

  • THC-Val-HS的溶解度较THC提高96倍,体外通透性也明显改善。
  • 含THC-Val-HS的制剂在麻醉兔眼前段组织递送THC:房水62.1 ng/100 μL,虹膜睫状体51.4 ng/50 mg(总THC)。
  • THC-Val-HS降眼压持续时间较THC延长1小时,降幅较THC增大10%,与毛果芸香碱滴眼液相当。
  • 噻吗洛尔滴眼液的降眼压作用持续时间长于THC-Val-HS。
  • 清醒动物多次给予THC-Val-HS后,眼组织中可检出THC和THC-Val-HS;在60和120分钟时点,虹膜睫状体中THC浓度(53和57.4 ng/50 mg)显著高于THC-Val-HS(24.2和11.3 ng/50 mg)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of the present study was to evaluate the utility of the relatively hydrophilic Δ9-tetrahydrocannabinol (THC) prodrugs, mono and di-valine esters (THC-Val and THC-Val-Val) and the amino acid (valine)-dicarboxylic acid (hemisuccinate) ester (THC-Val-HS), with respect to ocular penetration and intraocular pressure (IOP) lowering activity. THC, timolol, and pilocarpine eye drops were used as controls. METHODS: THC-Val, THC-Val-Val, and THC-Val-HS were synthesized and chemically characterized. Aqueous solubility and in vitro transcorneal permeability of THC and the prodrugs, in the presence of various surfactants and cyclodextrins, were determined. Two formulations were evaluated for therapeutic activity in the α-chymotrypsin induced rabbit glaucoma model, and the results were compared against controls comprising of THC emulsion and marketed timolol maleate and pilocarpine eye drops. RESULTS: THC-Val-HS demonstrated markedly improved solubility (96-fold) and in vitro permeability compared to THC. Selected formulations containing THC-Val-HS effectively delivered THC to the anterior segment ocular tissues in the anesthetized rabbits: 62.1 ng/100 μL of aqueous humor (AH) and 51.4 ng/50 mg of iris ciliary bodies (IC) (total THC). The duration and extent of IOP lowering induced by THC-Val-HS was 1 hour longer and 10% greater, respectively, than that obtained with THC and was comparable with the pilocarpine eye drops. Timolol ophthalmic drops, however, exhibited a longer duration of activity. Both THC and THC-Val-HS were detected in the ocular tissues following multiple dosing of THC-Val-HS in conscious animals. The concentration of THC in the iris-ciliary bodies at the 60- and 120-minute time points (53 and 57.4 ng/50 mg) were significantly greater than that of THC-Val-HS (24.2 and 11.3 ng/50 mg). Moreover, at the two time points studied, the concentration of THC was observed to increase or stay relatively constant, whereas THC-Val-HS concentration decreased by at least 50%. A similar trend was observed in the retina-choroid tissues. CONCLUSIONS: A combination of prodrug derivatization and formulation development approaches significantly improved the penetration of THC into the anterior segment of the eye following topical application. Enhanced ocular penetration resulted in significantly improved IOP-lowering activity.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Adelli GR, Bhagav P, Taskar P, et al. Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability. Invest Ophthalmol Vis Sci. 2017. PMID: 28399267. doi:10.1167/iovs.16-20757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。